Related Experiment Video
Updated: Jun 28, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Long noncoding RNA NORAD regulates MPP+-induced Parkinson's disease model cells
Qingxin Song1, Yunming Geng2, Yue Li3
1Department of Neurosurgery, Linyi People's Hospital, Linyi, Shandong Province, 276000, China.
Journal of Chemical Neuroanatomy
|August 18, 2019
Summary
Long non-coding RNA NORAD protects against Parkinson's disease (PD) cytotoxicity. Upregulating NORAD in a cell model reduced PD-like cell death, while downregulating it worsened the damage.
Area of Science:
- Molecular Biology
- Neuroscience
- Genetics
Background:
- Long non-coding RNAs (lncRNAs) are implicated in human diseases, but their role in neurodegenerative disorders like Parkinson's disease (PD) remains unclear.
- Investigating lncRNAs in PD pathogenesis is crucial for understanding disease mechanisms and developing therapeutic strategies.
Purpose of the Study:
- To investigate the functional role of the lncRNA NORAD in a cellular model of Parkinson's disease (PD).
- To determine the effect of NORAD modulation on 1-methyl-4-phenylpyridinium (MPP+)-induced cytotoxicity in human neuroblastoma SH-SY5Y cells.
Main Methods:
- Established a human neuroblastoma SH-SY5Y cell line as an in vitro PD model using MPP+ treatment.
- Quantified NORAD expression changes in response to MPP+ using qRT-PCR.
- Utilized lentiviral transduction to upregulate or downregulate NORAD expression.
- Assessed the impact of NORAD modulation on cell death, apoptosis, caspase 3/7, ROS, and LDH activities.
Main Results:
- MPP+ treatment downregulated NORAD expression in a dose- and time-dependent manner.
- NORAD upregulation protected SH-SY5Y cells against MPP+-induced cytotoxicity, reducing cell death and apoptosis.
- Upregulating NORAD decreased MPP+-induced caspase 3/7, ROS, and LDH activities, while downregulation exacerbated cytotoxicity.
Conclusions:
- lncRNA NORAD plays a protective role in regulating Parkinson's disease (PD) pathogenesis.
- NORAD may serve as a potential therapeutic target for PD treatment.
More Related Videos
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Related Concept Videos
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
02:27Nonsense-mediated mRNA Decay
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...